Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PC DLBCL-LT) there are no uniform recommendations for second-line treatment in case of relapse. Case presentation: Here we present the case of an elderly relapsed/refractory PC DLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.
Zoli, S., Pellegrini, C., Casadei, B., Broccoli, A., Argnani, L., Nanni, L., et al. (2023). Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report. CHEMOTHERAPY, 1, 23-26 [10.1159/000534784].
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report
Zoli, Sabrina;Pellegrini, Cinzia;Casadei, Beatrice;Broccoli, Alessandro;Argnani, Lisa;Nanni, Laura;Stefoni, Vittorio;Zinzani, Pier Luigi
2023
Abstract
Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PC DLBCL-LT) there are no uniform recommendations for second-line treatment in case of relapse. Case presentation: Here we present the case of an elderly relapsed/refractory PC DLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.| File | Dimensione | Formato | |
|---|---|---|---|
|
Zoli_2023.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
375.12 kB
Formato
Adobe PDF
|
375.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
